Illumina, Inc. vs iShares Russell 2000 ETF — how do they compare? Illumina, Inc. trades at $192.38 (market cap $29.12B), while iShares Russell 2000 ETF trades at $302.95. The key difference: iShares Russell 2000 ETF is trading nearer its 52-week high, Illumina, Inc. nearer its low. Which is the better fit depends on your goals.
| ILMN | IWM | |
|---|---|---|
Market Cap | $29.12B | — |
Sector | Health | — |
52-Week High | $205.10 | $301.69 |
52-Week Low | $91.00 | $225.45 |
Enterprise Value | $30.48B | — |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $192.57, up 0.4% on the day, with a bearish technical signal but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $1.31 exceeding expectations. Revenue remains stable around $4.3B, and profitability has improved significantly, with a net income margin of 19.57% in 2025. The company maintains robust cash flow from operations of $1.08B in 2025.
The outlook is mixed; strong fundamentals and analyst buy ratings support upside to the $201.58 consensus target, but technical weakness and high valuation ratios pose near-term risks. Key opportunities include sustained earnings beats and AI initiatives, while risks involve competitive pressures and execution challenges in a volatile market.
IWM, the iShares Russell 2000 ETF tracking US small-cap stocks, trades at $302.33 with a 0.78% daily gain. Technical indicators show a bullish trend with strong moving average support, though RSI suggests potential overbought conditions. The ETF benefits from institutional preference due to its liquidity and options ecosystem, with recent news highlighting small-cap outperformance versus large caps in 2026.
Outlook remains positive as small caps lead market gains, but risks include higher volatility and competition from lower-cost alternatives. Institutional inflows and broadening market participation support further upside, though valuation concerns and economic sensitivity warrant monitoring.
Trailing returns across standard periods
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on IWM →